The Brown University Psychopharmacology Update
April 30, 2026
Four weekly doses of TSND‐201 (methylone), an analog of 3,4 methylenedioxymethamphetamine (MDMA), resulted in significant improvement relative to placebo in reducing symptoms of post‐traumatic stress disorder (PTSD), a Phase 2 study has found. Treatment‐emergent adverse events associated with TSND‐201 were generally mild to moderate in severity, with no significant suicidal ideation. Study...
Scientific Reports
April 25, 2026
Audrey G. Evers, Elizabeth C. Stade, Aadesh Salecha et al.
1 citation
Enthusiastic media coverage of psychedelics as a treatment for mental health disorders is perceived as hyped compared to coverage of established treatments. To measure potential hype, we conducted pre-registered analyses comparing media coverage (e.g., newspaper articles) of psychedelics to FDA-approved antidepressants for major depressive disorder and posttraumatic stress disorder. We used...
Clinical and Preventive Medicine
April 20, 2026
Mykola Didukh, K. Freytag, Vitalii Lunov et al.
Introduction. Following the full-scale Russian invasion of Ukraine, there has been a substantial increase in the need for accessible, rapid-acting, and non-pharmacological approaches to alleviate symptoms of post-traumatic stress disorder and depression among Ukrainian refugees. One potentially useful intervention is the Transcendental Meditation program. Aim. To assess the effectiveness of the...
L'Encephale
April 7, 2026
Déborah Eymond, Alyson Miquel, Anais Duffaud et al.
Military personnel are frequently exposed to traumatic situations that can lead to chronic post-traumatic stress disorder (PTSD). PTSD complicates their reintegration due to the high risk of retraumatization. To support the reintegration of injured servicemen and women, the army has developed the Omega program which includes courses at the Centre des Blessés de l'Armée de Terre (CReBAT). These...
Zenodo (CERN European Organization for Nuclear Research)
April 7, 2026
Psychedelic-assisted therapy for PTSD tends to produce mild, transient adverse effects, but concerns about long-term safety and inconsistent reporting of adverse events highlight the need for further research.
Frontiers in Psychiatry
April 7, 2026
Ravi Philip Rajkumar
Post-traumatic stress disorder (PTSD) is a chronic mental illness that occurs following exposure to traumatic stressors such as combat, disasters, or assault. It is characterized by a triad of reexperiencing of the trauma, avoidance of triggers for such recollections, and increased vigilance towards threats (1). In 1992, Judith Herman described a variant of PTSD that occurred in persons who had...